- Home
- LTRX vs ACRS Comparison
LTRX vs ACRS Comparison
Compare LTRX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRX
- ACRS
- Stock Information
- Founded
- LTRX 1989
- ACRS 2012
- Country
- LTRX United States
- ACRS United States
- Employees
- LTRX N/A
- ACRS N/A
- Industry
- LTRX Computer Communications Equipment
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- LTRX Telecommunications
- ACRS Health Care
- Exchange
- LTRX Nasdaq
- ACRS Nasdaq
- Market Cap
- LTRX 186.8M
- ACRS 198.2M
- IPO Year
- LTRX 2000
- ACRS 2015
- Fundamental
- Price
- LTRX $4.95
- ACRS $1.90
- Analyst Decision
- LTRX Strong Buy
- ACRS Strong Buy
- Analyst Count
- LTRX 4
- ACRS 9
- Target Price
- LTRX $4.63
- ACRS $9.25
- AVG Volume (30 Days)
- LTRX 438.9K
- ACRS 1.1M
- Earning Date
- LTRX 11-06-2025
- ACRS 11-05-2025
- Dividend Yield
- LTRX N/A
- ACRS N/A
- EPS Growth
- LTRX N/A
- ACRS N/A
- EPS
- LTRX N/A
- ACRS N/A
- Revenue
- LTRX $122,923,000.00
- ACRS $16,789,000.00
- Revenue This Year
- LTRX $4.81
- ACRS N/A
- Revenue Next Year
- LTRX $11.85
- ACRS $7.02
- P/E Ratio
- LTRX N/A
- ACRS N/A
- Revenue Growth
- LTRX N/A
- ACRS N/A
- 52 Week Low
- LTRX $1.91
- ACRS $1.05
- 52 Week High
- LTRX $5.45
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- LTRX 63.73
- ACRS 51.51
- Support Level
- LTRX $4.42
- ACRS $1.81
- Resistance Level
- LTRX $5.45
- ACRS $1.94
- Average True Range (ATR)
- LTRX 0.27
- ACRS 0.10
- MACD
- LTRX 0.01
- ACRS -0.01
- Stochastic Oscillator
- LTRX 69.90
- ACRS 46.34
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.